1 Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine

2 Expressing SARS-CoV-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial

3 Authors

- 4 Vu Dinh Thiem MD¹, Dang Duc Anh MD¹, Vu Hai Ha MD¹, Nguyen Van Thom MD², Tran Cong Thang MD³, Jose
- 5 Mateus PhD⁴, Juan Manuel Carreño PhD^{5, 6}, Rama Raghunandan PhD⁷, Nguyen Mai Huong BPharm³, Laina D Mercer
- 6 PhD⁷, Jorge Flores MD⁷, E Alexandar Escarrega MS⁴, Ariel Raskin BA^{5,6}, Duong Huu Thai MD⁸, Le Van Be MD⁸,
- 7 Alessandro Sette Dr.Biol.Sc^{4,9}, Bruce L Innis MD⁷, Florian Krammer PhD^{5,6,10}, Daniela Weiskopf PhD^{4,9}

8 Author affiliations

- 9 ¹National Institute of Hygiene and Epidemiology, 1 Yersin Street, Hai Ba Trung District, Hanoi, Vietnam
- 10 ² Center for Disease Control, Thai Binh Province, 10 Hoàng Công Chất street, Quang Trung ward, Thai Binh, Vietnam
- ³ PATH Vietnam, Hanoi Towers, 49 Hai Ba Trung Street, Hoan Kiem District, Hanoi, Vietnam
- ⁴Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA
- ⁵ Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.
- ⁶ Center for Vaccine Research and Pandemic Preparedness (C-VaRPP) at Mount Sinai New York, New York, NY,
- 15 USA
- ⁷ Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.
- ⁸ Institute of Vaccines and Medical Biologicals, 9 Pasteur, Xuong Huan, Nha Trang City, Khanh Hoa, Vietnam
- ⁹ Department of Medicine, University of California, San Diego (UCSD), La Jolla, CA, 92037, USA
- ¹⁰ Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New
- 20 York, New York, USA
- 21 Correspondence to:
- 22 Rama Raghunandan, mailto:rraghunandan@path.org, +1-301-793-6132
- 23 Florian Krammer, florian.krammer@mssm.edu, +1-212-241-8166
- 24 Daniela Weiskopf, daniela@lji.org, +1-858-752-6919
- 25

26

27 Summary

28 Background

- 29 Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and lower-middle-income countries
- 30 is needed. NDV-HXP-S is an inactivated egg-based recombinant Newcastle disease virus vaccine expressing the spike
- 31 protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A public sector manufacturer in Vietnam
- 32 assessed the immunogenicity of NDV-HXP-S (COVIVAC) relative to an authorized vaccine.

33 Methods

- This phase 2 stage of a randomised, observer-blind, controlled, phase 1/2 trial was conducted at three community health centers in Thai Binh Province, Vietnam. Healthy males and non-pregnant females, 18 years of age and older,
- 36 were eligible. Participants were randomised by age (18-59, ≥ 60 years) to receive one of three treatments by
- intramuscular injection twice, 28 days apart: COVIVAC at 3 μ g or 6 μ g, or AstraZeneca COVID-19 vaccine
- VAXZEVRIA. Participants and personnel assessing outcomes were masked to treatment. The main outcome was the
- 39 induction of 50% neutralising antibody titers against vaccine-homologous pseudotyped virus 14 days (day 43) and 6
- 40 months (day 197) after the second vaccination by age group. The primary immunogenicity and safety analyses
- 41 included all participants who received one dose of the vaccine. ClinicalTrials.gov NCT05940194.

42 Findings

43 During August 10-23, 2021, 737 individuals were screened, and 374 were randomised (124-125 per group); all 44 received dose one, and three missed dose two. On day 43, the geometric mean fold rise of 50% neutralising antibody 45 titers for subjects age 18-59 years was 31·20 (COVIVAC 3 μg N=82, 95% CI 25·14-38·74), 35·80 (COVIVAC 6 μg; N=83, 95% CI 29·03-44·15), 18·85 (VAXZEVRIA; N=82, 95% CI 15·10-23·54), and for subjects age ≥60 years was 46 37·27 (COVIVAC 3 μg; N=42, 95% CI 27·43-50·63), 50·10 (COVIVAC 6 μg; N=40, 95% CI 35·46-70·76), 16·11 47 48 (VAXZEVRIA; N=40, 95% CI 11.73-22.13). Among subjects seronegative for anti-S IgG at baseline, the day 43 49 geometric mean titer ratio of neutralising antibody (COVIVC 6 µg/VAXZEVRIA) was 1.77 (95% CI 1.30-2.40) for 50 subjects age 18-59 years and 3.24 (95% CI 1.98-5.32) for subjects age ≥ 60 years. On day 197, the age-specific ratios 51 were 1.11 (95% CI 0.51-2.43) and 2.32 (0.69-7.85). Vaccines were well tolerated; reactogenicity was predominantly 52 mild and transient. The percentage of subjects with unsolicited adverse events (AEs) during 28 days after vaccinations 53 was similar among treatments (COVIVAC 3 µg 29.0%, COVIVAC 6 µg 23.2%, VAXZEVRIA 31.2%); no vaccine-54 related AE was reported.

55 Interpretation

- 56 Considering that induction of neutralising antibodies against SARS-CoV-2 has been correlated with the efficacy of
- 57 COVID-19 vaccines, including VAXZEVRIA, our results suggest that vaccination with COVIVAC may afford
- 58 clinical benefit matching or exceeding that of the VAXZEVRIA vaccine.

59 Funding

- 60 Vietnam's Institute of Vaccines and Medical Biologicals (including support from Vietnam's national COVID-19
- 61 vaccine fund and a charitable contribution from the Thien Tam fund of Vin group), Coalition for Epidemic
- 62 Preparedness Innovations, a charitable contribution from Bayer AG, US National Institutes of Health.

64 Introduction

- The coronavirus disease 2019 (COVID-19) pandemic has resulted in millions of deaths, burdened healthcare systems globally, and exposed vaccine access inequities worldwide. A systematic study to assess the impact of delayed supply of COVID-19 vaccines indicated that only 25% of the population in low- and lower-middle-income countries received at least one dose of vaccine as of October 2022.¹ Ensuring an adequate supply of COVID-19 vaccines for low- and lower-middle-income countries (LMICS), which constitute 85% of the global population, is essential.
- As of March 2023, Vietnam's Ministry of Health recorded 11,525,408 COVID-19 cases, ranking 13th in amount of
- cases among 230 countries and territories worldwide.² Although imported vaccines and infection-induced immunity
- have reduced the risk of disease, the threat from new viral variants and the potential need for vaccinating elderly adults
- and other at-risk individuals annually highlight the value to Vietnam of access to domestically produced COVID-19
- 74 vaccines as a sustainable asset.
- The rapid rollout of COVID-19 vaccines saved millions of lives globally.³ By inducing potent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, COVID-19 vaccines reduce the risk of severe disease, with the level of antibodies induced correlated with vaccine efficacy.⁴⁻⁵ However, the emergence of Omicron sub-lineage variants with increased transmissibility and escape from pre-existing neutralising antibodies emphasizes the importance of confirming that new COVID-19 vaccine candidates also induce cellular immunity.⁶
- 80 PATH and the Icahn School of Medicine at Mount Sinai collaborated with Vietnam's Institute of Vaccines and 81 Medical Biologicals (IVAC), a manufacturer of egg-based inactivated influenza vaccines, to develop an egg-based inactivated Newcastle disease virus vaccine expressing a six-proline prefusion-stabilized SARS-CoV-2 spike (NDV-82 HXP-S COVID-19 vaccine, also known as COVIVAC).⁷ In a phase 1 trial (NCT04830800), COVIVAC 83 administered twice 28 days apart had an acceptable safety and immunogenicity profile in healthy adults 18-59.8 For 84 85 the next stage of clinical development, IVAC sponsored a phase 2 trial in which the safety and immunogenicity of 86 COVIVAC at two dosage levels, in adults with stable health including individuals ≥ 60 years of age, was contrasted 87 with AstraZeneca's adenovirus vectored COVID-19 vaccine (VAXZEVRIA)⁹ then the authorized pandemic vaccine 88 most commonly administered in Vietnam. The study aimed to demonstrate that COVIVAC induced a superior 89 neutralising antibody response to vaccine-homologous SARS-CoV-2 relative to VAXZEVRIA. The study also aimed 90 to explore the activation of SARS-CoV-2 spike-specific T cells by COVIVAC versus VAXZEVRIA. This report 91 provides the results of that clinical trial, including the induction of virus neutralising antibodies against pseudotyped 92 and wild-type (live virus) vaccine-homologous SARS-CoV-2 and virus-specific T-cell activation

93 Methods

94 Study design and participants

95 This phase 2 stage (NCT05940194) of a randomised, observer-blind, controlled, phase 1/2 trial was conducted at three 96 community health centers within the Vu Thu District Health Center catchment, Thai Binh Province, Vietnam. 97 Investigators from Vietnam's National Institute of Hygiene and Epidemiology (NIHE) collaborated with staff of the 98 community health centers, district health center, district hospital, and the Provincial Center for Disease Control to 99 perform the study. Participants were recruited following community outreach. Males and non-pregnant females (sex 100 or gender was self-reported) with stable health, 18 years of age and older, with body mass index 17 to 40 kg/m², with 101 no history of confirmed COVID-19 or infection with human immunodeficiency virus, were eligible to participate. A 102 negative urinary pregnancy test was required of women with reproductive capacity before administering each study

103 vaccine dose. Complete eligibility criteria are described in the trial protocol provided in the supplementary material.

104 Written informed consent was obtained from all participants. The trial complied with the Declaration of Helsinki and

105 Good Clinical Practice. This study was jointly approved by the Institutional Review Board of the Vietnam National

106 Institute of Hygiene and Epidemiology and the Independent Ethics Committee of the Vietnam Ministry of Health ref

107 no. 1407/QD-BYT.

108 Randomisation and masking

109 Subjects (N=374) were randomly allocated to one of three equal groups (COVIVAC 3 µg, COVIVAC 6 µg, or the

- 110 comparator VAXZEVRIA) using a computer-generated randomisation sequence prepared by an unblinded statistician.
- 111 Randomisation was age-stratified, with approximately one-third of subjects aged ≥ 60 years. An unmasked pharmacist
- 112 dispensed each treatment according to the randomisation sequence to an unmasked vaccinator. All participants and
- study personnel, besides the unmasked pharmacy team and vaccinators, were masked for treatment.

114 **Procedures**

115 The recombinant NDV-HXP-S vaccine (COVIVAC) was manufactured according to current Good Manufacturing 116 Practice (GMP) by IVAC in their Influenza Vaccine Plant (Nha Trang, Vietnam), as previously described.⁸ The 117 adenovirus vectored vaccine from AstraZeneca (ChAdOx1; VAXZEVRIA), used as a comparator vaccine, was sourced from the Ministry of Health. Unmasked vaccinators administered study treatments by intramuscular injection 118 119 of 0.5 mL on study days 1 and 29. Subjects were observed in the clinic for 30 min after each vaccination. Blood 120 samples were drawn for immunogenicity endpoints before vaccination on days 1 (first dose), 43 (14 days post dose two), and 197 (6 months post dose two). Subjects randomly allocated to a cell-mediated immunity subset (N=12 per 121 122 treatment group) had additional blood collected on days 1 and 43 to isolate peripheral blood mononuclear cells 123 (PBMCs); these were stored in liquid nitrogen until analysed. Solicited injection site reactions (pain/tenderness, 124 swelling/induration, erythema) and systemic symptoms (headache, fatigue, malaise, myalgia, arthralgia,

125 nausea/vomiting, and fever defined as oral temperature $\geq 38^{\circ}$ C) were recorded by subjects in a diary card for seven

- 126 days post-vaccination that included intensity, which the investigators then reported. Subjects also recorded unsolicited
- 127 adverse events (AEs) for 28 days after each vaccine dose and reported them at scheduled clinic visits, whereupon the
- 128 investigator included these in the study database after interviewing the subjects, grading them for intensity as
- 129 previously described,⁸ assessing them for causality, and categorizing them as severe or not. Severe AEs were collected
- 130 for the duration of the study. A Data Safety Monitoring Board (DSMB) monitored unblinded safety data.

131 We measured anti-SARS-CoV-2 spike IgG using a validated indirect enzyme-linked immunosorbent assay (ELISA)

132 at Nexelis (Laval, Canada), as described.⁸ Concentrations were transformed to binding antibody units per mL

- 133 (BAU/mL), based on the World Health Organization (WHO) International Standard for anti-SARS-CoV-2
- immunoglobulin using a conversion factor determined during assay validation (1/7.9815). The assay's cut-off and
- lower limit of quantitation (LLOQ) were 6.3 BAU/mL.

136 We measured serum neutralising activity against the Wuhan-Hu-1 strain of SARS-CoV-2 in a validated pseudotyped

137 virus neutralization assay (PNA)⁸ that assessed particle entry inhibition.¹⁰ The neutralising titer of a serum sample was

138 calculated as the reciprocal serum dilution corresponding to the 50% neutralisation antibody titer (NT_{50}) for that

- 139 sample; the NT₅₀ titers may be transformed to international units per mL (IU/mL), based on the WHO international
- 140 standard for anti-SARS-CoV-2 immunoglobulin, using a conversion factor determined during assay validation
- 141 (1/1.872). The assay's cut-off and lower limit of quantitation (LLOQ) were 5.3 IU/mL (10 as the NT₅₀ titer value)
- 142 and 5.9 IU/mL, respectively.

143 We also measured live virus neutralising activity as a 50% inhibitory dilution (ID_{50}) against a wild-type SARS-CoV-

144 2 isolate (USA-WA1/2020, catalog number NR-52281; BEI Resources) using an assay performed in a biosafety level

145 3 facility as previously described.¹¹ Briefly, Vero.E6 cells (20,000 cells/100 μL per well) were seeded onto sterile 96-

146 well cell culture plates a day prior to the neutralisation assay. Sera were serially diluted in minimal essential medium

- 147 (MEM; Life Technologies) at a 1:10 starting dilution. One thousand (1,000) median tissue culture infectious doses
- 148 (TCID₅₀s) of the virus were incubated with diluted sera for 1 hour inside a biosafety cabinet. Media from confluent
- 149 cell monolayers (90%) was removed, and 120 μ L of the virus-serum dilutions were added to the cells for 1 h at 37°C.
- 150 The mixture was removed and 100 µL of each corresponding serum dilution was added per well. Additionally, 100

151 μL of MEM was added to every well. Remdesivir at 10 μM was used as control. Plates were incubated at 37°C for

- 152 48 hours, media was removed, and cells were fixed with 150 μL of 10% formaldehyde (Polysciences) per well. After
- 153 fixation, cells were permeabilized and stained using the 1C7C7 mAb.¹¹ The live virus neutralisation assay (LVNA)
- 154 cutoff (ID₅₀) was 1:10.
- 155 To assess the breadths of the adaptive immune response, we measured vaccine-induced spike-specific T cells in PBMC
- 156 samples utilizing a T cell receptor (TCR) dependent activation induced markers (AIM) assay.¹²⁻¹³ AIM assays have
- 157 been comprehensively used to compare COVID-19 vaccine-induced T cell responses.¹⁴⁻¹⁵ This assay measures antigen

specific T cells based on upregulation of activation markers, irrespective of cytokines.¹⁶ Antigen-specific CD4+ and 158 CD8+ T cells were measured as a percentage of AIM+ T cells+ as described before.^{14.16-17} Briefly, PBMC were thawed 159 160 and plated in 96-wells U-bottom plates at 1x10⁶ PBMC per well, then blocked at 37°C for 15 min with 0.5 µg/ml anti-161 CD40 mAb (Miltenvi Biotec), and fluorescently labeled with chemokine receptor antibodies (anti-CCR6, CXCR5, 162 CXCR3, and CCR7) (see Supplement Table 1 for list of antibodies used). Cells were incubated at 37°C for 24 hrs 163 with a spike-specific peptide mega pool (MP; 1 µg/ml); controls were dimethyl sulfoxide (DMSO, an equimolar 164 amount) and phytohaemagglutinin PHA (2.5 µg/ml). The mega pool (MP) approach, previously described, enables 165 simultaneous testing of a large number of epitopes, facilitating the characterization of T-cell responses to infectious diseases.¹³⁻¹⁴ We stimulated the PBMCs ex vivo to evaluate the antigen-specific T cell response against SARS-CoV-166 2. The spike MP has 253 overlapping peptides spanning the entire sequence of the spike protein.¹⁸ SARS-CoV-2 spike-167 168 specific circulating CD4+ T cells and spike-specific circulating CD8+ T cells were measured by surface co-expression 169 of OX40+CD137+ and CD69+CD137+, respectively. SARS-CoV-2 spike-specific circulating follicular helper T 170 (cT_{FH}) cells were measured as CXCR5+OX40+surface CD40L+ and quantified as a percentage of CD4+ T cells after

- 171 stimulation with spike MP. The samples were acquired on a Cytek Aurora (Cytek Biosciences). The gating strategy
- is shown in Supplement Figure 1.

173 Outcomes

- 174 The primary outcomes were safety and induction of neutralising antibodies by COVIVAC, comparing 3 µg to 6µg 175 and each COVIVAC group to the VAXZEVRIA group. The safety of each treatment was evaluated as the number
- and severity of solicited injection site and systemic AEs during 7 days after vaccination. Number, severity, and
- 177 relatedness of unsolicited (spontaneously reported) AEs during 28 days after each vaccination; and occurrence of
- medically attended AEs, serious AEs, and AEs of special interest throughout the 7-month study period. Induction of
- neutralising antibody measured by PNA was expressed as a geometric mean titer (GMT) at 14days post second
- 180 vaccination, a GMT ratio in subjects seronegative at baseline, a geometric mean fold rise (GMFR), and a percentage
- 181 of subjects with a \geq 4-fold increase from baseline regardless of baseline anti-spike IgG seropositivity. A secondary
- 182 immunogenicity outcome was the induction of anti-spike IgG in binding antibody units (BAU/mL) expressed in the
- 183 same four parameters used for the neutralising activity. The exploratory immunogenicity outcomes were the induction
- 184 of neutralising antibodies to wild-type SARS-CoV-2 expressed as a GMT and GMT ratio (COVIVAC/VAXZEVRIA)
- 185 at 14days post second vaccination, and the frequency of spike-specific activated T cells.

186 Statistical analysis

- 187 This study (ClinicalTrials.gov NCT05940194) was descriptive with no confirmatory objective, as it was intended to
- assess the feasibility of advancing the evaluation of COVIVAC towards emergency use authorization based on
- 189 superiority to the comparator. The study had >90% power to demonstrate a lower bound of the 95% confidence interval
- 190 (CI) of the GMT ratio greater than 1.0 if the observed ratio (COVIVAC/VAXZEVRIA) was \geq 1.65. The study also
- 191 had >95% power to detect at least one serious or severe adverse event if the underlying rate was $\geq 2.5\%$ and power

192 was >80% to detect differences in AE rates \geq 15%. All statistical tests were two-sided with a significance level of 0.05. 193 All statistical analyses were performed using SAS version 9.4. All safety assessments occurred in the treatment-194 exposed population, according to the treatment received. All treatment group percentages were supplemented with 195 two-sided 95% confidence intervals (CIs) computed via the Clopper-Pearson method. The immunogenicity analysis 196 presented was performed in the full analysis population that included all subjects randomised for whom any post-197 vaccination immunogenicity data were available. This population is identical to the per-protocol population at Day 198 43. Geometric mean antibody responses were reported by treatment and time point, accompanied by 95% CIs. The 199 analysis of geometric means excluded subjects who were seropositive at baseline (defined by anti-spike IgG >LLOQ 200 as measured by ELISA). Geometric mean fold rises (GMFR) were calculated relative to baseline using the log 201 difference of the paired samples, with corresponding CIs computed via the t-distribution, utilizing the antilog 202 transformation to present the ratio. The proportions of subjects with GMFRs of NT50 >4 from baseline were 203 summarized with two-sided 95% confidence intervals computed via the Clopper-Pearson method. The analysis of 204 immunogenicity relative to baseline included baseline seropositive subjects. The CD4+ T cell responses were 205 summarized via the geometric mean and treatment groups were compared via the Mann-Whitney U test.

206 **Role of the funding source**

207 The funders of the study had no role in data collection, data analysis, or writing of the statistical report. IVAC was the

208 clinical trial sponsor and approved the study protocol. IVAC employees contributed as authors by preparing the

209 investigational vaccine, interpreting data, and critically reviewing this report. All authors had full access to all data in

210 the study and accepted responsibility for the decision to submit for publication.

211 Results

- From August 10 to 23, 2021, 737 individuals were screened and 374 were randomised to three treatment groups (124-
- 213 125 subjects per group). All received dose one; three missed dose two; 365 completed the last study visit on day 197
- 214 (Figure 1). The baseline characteristics are shown by treatment group in Table 1; the exposed population was 49.5%
- 215 male, had a mean age of 49 years (range 18-77) and a mean body mass index of 22.29 (range 17.01-31.76).

Trial participants from all three vaccine groups tolerated the doses with no dose-limiting reactogenicity. Solicited 216 217 injection site reactogenicity was mostly mild during the seven days after each vaccination (Table 2). Pain or tenderness 218 was the most common injection site symptom recorded, more frequently following dose one than dose two. Post-dose 219 one-injection site pain was reported by 72% of VAXZEVRIA recipients but by only 46-56% of COVIVAC recipients. 220 The most common systemic symptoms (Table 2) were fatigue or malaise, headache, and myalgia, reported more 221 frequently following dose one than dose two. Notably, fever (\geq 38°C) following dose one occurred in 22.4% of 222 VAXZEVRIA recipients but in only 0.8% of COVIVAC recipients. Unsolicited adverse events occurring 28 days 223 after vaccination (Supplement Table 2) were reported by a similar proportion of subjects in each treatment group 224 (23·2-31·2%); none of these events were judged by the investigator to be treatment-related or led to withdrawal from 225 the trial. Although six serious adverse events were reported during the entire study period (three in each COVIVAC 226 treatment group), none were considered treatment-related (intestinal obstruction, sialadenitis, leukemia, COVID-19, 227 colon cancer, and gastric cancer). The independent DSMB expressed no safety concerns.

228 The main immunogenicity measure was the induction of vaccine-homologous antibodies assessed by PNA 14 days 229 after vaccine dose two. Figure 2 shows plots of neutralising (PNA) antibody GMT by age and treatment group over 230 time among the 95% of subjects seronegative at baseline for anti-S IgG and with a valid assay result (see also 231 Supplement Table 3). Responses to COVIVAC were significantly higher than to VAXZEVRIA 14 days after vaccine 232 dose two, although this contrast was not statistically significant six months after vaccine dose two. Note that six 233 months after dose two, GMTs remained well above baseline, with increases in two groups among adults 18-59 years 234 of age, presumably due to intercurrent infection with SARS-CoV-2. The percentage of subjects 18-59 years of age 235 mounting a minimum four-fold PNA response to vaccination 14 days after vaccine dose two was 89.0% (95% CI 80·2-94·9) for COVIVAC 3µg, 92·8% (95% CI 84·9-97·3) for COVIVAC 6µg, and 85·4% (95% CI 75·8-92·2) for 236 237 VAXZEVRIA. Equally high PNA response rates were also observed in COVIVAC vaccinees ≥60 years of age 238 (Supplement Table 4). Notably, the magnitude of neutralising antibody induction 14 days after dose two, expressed 239 as a PNA GMFR from baseline, although similar between COVIVAC groups, was greater compared to the 240 VAXZEVRIA group (Table 3) for subjects 18-59 years of age and for subjects ≥ 60 years of age. The greater peak 241 induction of neutralising antibodies by COVIVAC relative to VAXZEVRIA was also apparent in the GMT ratios 242 (COVIVAC/VAXZEVRIA) for both dose levels with 95% confidence intervals that excluded 1.00 for both age strata 243 (Supplement Table 5).

244 To confirm the observation of COVIVAC's superior peak induction of vaccine-homologous neutralizing antibodies,

- 245 we evaluated the GMT of neutralising antibodies measured by live virus neutralizing assay (LVNA) induced by two
- doses of 3µg or 6µg of COVIVAC and compared it with neutralising antibodies induced by VAXZEVRIA. Although
- the GMTs measured by live virus assays were approximately two thirds less than mean titers measured by pseudotyped
- 248 virus, the GMT ratios estimated for the two COVIVAC groups relative to the VAXZEVRIA group by either assay
- 249 were 1.5 to 2.0-fold higher in a dose-dependent manner (Supplement Table 6).
- 250 A secondary immunogenicity outcome was the induction of anti-spike IgG in binding antibody units (BAU/mL). By
- this measure of immunogenicity, VAXZEVRIA induced higher peak concentrations of anti-spike IgG measured by
- 252 ELISA than did COVIVAC at either dose or for both age strata (Supplement Tables 7–9). For instance, the GMC ratio
- 253 (COVIVAC 3µg/VAXZEVRIA) at 14 days after vaccine dose two in subjects 18-59 was 0.38 (95% CI, 0.29-0.50),
- and in those ≥ 60 was 0.47 (95% CI 0.28-0.78). Six months after dose two, the 95% CI for the GMC ratios included
- 255 1.00. This aligns with earlier observations showing that inactivated NDV-HXP S induces higher neutralising antibody-
- 256 to-spike binding antibody ratios compared to other vaccine platforms.¹⁹
- 257 Finally, we explored the induction of spike specific CD4+ T cell responses by COVIVAC and VAXZEVRIA in a
- random subset of vaccinated individuals with no detectable anti-spike IgG by ELISA at baseline. Spike specific CD4+
- 259 T cell response was assessed utilizing an activation-induced molecules (AIM) assay, which evaluates the frequency
- of antigen-specific T cells based on the co-expression of OX40 and CD137 for CD4+ T cells and CD69 and CD137
- of CD8+T cells (Figure 3). We detected induction of a spike specific CD4+ T cell response on day 43 in all of 10
- 262 COVIVAC 3 μg vaccinees with a 0.14% cell frequency (95% CI 0.074-0.27%), in 9 of 10 COVIVAC 6 μg vaccinees
- with a 0.092% cell frequency (95% CI 0.040-0.21%), and in all of 12 VAXZEVRIA vaccinees with a 0.18% cell
- 264 frequency (95% CI 0.095-0.34%) (Figure 3B). The intensity of spike specific CD4+ T cell induction on day 43 was
- similar among the treatment groups (Figure 3C).
- Follicular helper T ($T_{\rm FH}$) cells help B cells activate antibody production. As this T cell subset can be induced by SARS-
- 267 CoV-2 infection and COVID-19 vaccination, we evaluated the frequency of circulating T_{FH} cells by the AIM assay at
- 268 baseline (day 1) and post-dose two (day 43) (Figure 3E). cT_{FH} were detected on day 43 in 8 of 10 COVIVAC 3 µg
- 269 vaccinees with a 0.077% cell frequency (95% CI 0.020-0.097%), in 4 of 10 COVIVAC 6 µg vaccinees with a 0.044%
- 270 cell frequency (95% CI 0.041-0.14%), and in 9 of 12 VAXZEVRIA vaccinees with a 0.08% cell frequency (95% CI
- 271 0.040-0.16% (Figure 3E). As shown for the spike specific CD4+ T cells, the intensity of spike specific cT_{FH} cells
- induction on day 43 was similar among treatment groups (Figure 3F).
- 273 Antibody levels by PNA and frequencies of memory CD4+ T cells were significantly correlated for COVIVAC 3 ug
- 274 (r=0.824, p>0.0001), COVIVAC 6 ug (r=0.875, p>0.0001), and VAXZEVRIA (r=0.764, p>0.0001) (Figure 3G); this
- 275 finding is evidence of a coordinated cellular-humoral immune response in both COVIVAC and VAXZEVRIA
- 276 recipients.

- 277 Spike specific CD8+ T cells were also measured by AIM (CD69+ CD137+). We detected a response on day 43 in 1
- 278 of 10 COVIVAC 3 μg vaccinees with a 0.032% cell frequency (95% CI 0.0.028-0.0.036%), in 1 of 10 COVIVAC 6
- μg vaccinees with a 0.037% cell frequency (95% CI 0.023-0.052%), and in 3 of 11 VAXZEVRIA vaccinees with a
- 280 0.049% cell frequency (95% CI 0.029-0.069%) (Figure 3H). The intensity of CD8+ T cell responses detected on day
- 43 was low and similar among the treatment groups. (Figure 3I).

282 **Discussion**

This phase 2 study showed that COVIVAC (NDV-HXP-S), when administered as a two-dose series to adults, including those 60 years of age and older, has an acceptable safety profile. It is highly immunogenic, activating T cell responses, and eliciting neutralising antibody responses 14 days after vaccine dose two that are superior to those induced by the adenovirus vectored VAXZEVRIA comparator vaccine.

All treatments evaluated were well tolerated with predominantly mild and self-limited reactogenicity that was greater after dose one than after dose two. The COVIVAC formulations at 3 and 6 µg dose levels were less reactogenic after dose one than the VAXZEVRIA comparator with respect to self-reported pain at the injection site, myalgia, and incidence of fever. Otherwise, there were no notable differences. Overall, in this study of 374 participants, there were no spontaneously reported AEs attributed by investigators to vaccination and no concerns expressed by the DSMB

292 providing safety oversight.

293 In terms of neutralising antibody titers, measured in a PNA, both dose levels of COVIVAC showed superiority to 294 VAXZEVRIA within each age stratum at an early time point (14 days after dose two) with the trend continuing out to 295 month 6, even though statistical significance was not reached at the later time point. Superior induction of neutralizing 296 antibody by COVIVAC at both dose levels relative to VAXZEVRIA 14 days after vaccine dose two was confirmed 297 by exploratory testing using a live virus neutralization assay. Interestingly, spike-binding antibodies were lower in the 298 COVIVAC groups compared to the VAXZEVRIA group, hinting at a better ratio of neutralising to binding antibodies 299 for COVIVAC. In fact, it has been shown in an earlier study, that inactivated NDV-HXP-S vaccines induce better ratios of neutralising antibodies relative to spike binding IgG compared to mRNA vaccines.¹⁹ These findings are 300 301 important since neutralising antibodies to SARS-CoV-2 are a mechanistic correlate of protection^{5,20} and new SARS-302 CoV-2 vaccines (e.g. Corbevax and VLA2001) have been licensed based on immune-bridging of neutralising antibody titers.²¹⁻²² Our results suggest that the possibility could be open for COVIVAC or for similar NDV-based vaccines to 303 304 be developed by other manufacturers.

There was no improvement in the induction of vaccine homologous neutralising antibodies by doubling the dose from a 3 to 6 µg level. Considering the important dose effect on immunogenicity observed in the phase 1 trial comparing 10 and 3 µg dose levels, with no adverse impact on reactogenicity, further development of COVIVAC will likely revert to a 10 µg dose level.⁸

In this comparative study, spike specific CD4+ T cell responses were detected in 90-100% of a small subset of randomly selected individuals, all being seronegative for anti-spike IgG pre-vaccination, in test and comparator vaccine groups. This is comparable to what has been reported for other COVID-19 vaccines such as mRNA and adenovirus vector vaccines.¹⁴ Similarly, we have detected circulating T follicular helper cells in a substantial fraction of vaccinees, supported by the strong correlation of spike-specific CD4+ T cell responses and functional antibody

314 responses. In previous studies, we demonstrated that a coordinated cellular-humoral immune response is associated

315 with mild disease outcomes in infected individuals.^{14,18.}

316 This study has several limitations. First, it was a phase 2 trial of limited size with no clinical endpoint. Second, the 317 investigational and comparator vaccines expressed an ancestral spike immunogen. Moreover, the study population 318 was largely naïve to SARS-CoV-2 at the time they were vaccinated. Currently, COVID-19 vaccines are being 319 deployed for booster immunization in primed butat risk adults. While COVIVAC performed well by inducing neutralising antibodies, its use as a booster vaccine is yet to be evaluated. Vaccines with ancestral spike antigens are 320 321 obsolete now due to emergence of different variants, especially the Omicron variant family. Current recommendations 322 from regulatory authorities and WHO state that XBB-lineage spike antigens should be used in updated vaccines. GMP 323 seed viruses for COVIVAC with XBB.1.5 spike exist and can be used for manufacturing of strain-changed updated 324 vaccines. We did not evaluate induction of neutralising antibodies to vaccine heterologous variants, as this was outside 325 of the scope of this study. Nevertheless, we observed that COVIVAC induced CD4+ T cell responses comparable to the VAXZEVRIA comparator, and it has been reported that CD4+ T cell responses induced by the ancestral spike 326 protein are maintained and cross-recognize SARS-CoV-2 variants, from Alpha to Omicron.^{23,24} 327

328 Strengths of this study are the use of a fully validated functional antibody readout (PNA), the inclusion of older adults 329 with an age-stratified analysis showing preservation of immunogenicity despite increased age, the assessment of T 330 cell responses, and the selection of the VAXZEVRIA vaccine as a highly relevant immuno-bridging comparator. The 331 efficacy of the VAXZEVRIA vaccine has been demonstrated in multiple double-blind randomized clinical trials, 332 varying from approximately 70% against any symptomatic disease to >95% against severe disease and/or 333 hospitalization.²⁵ Multiple effectiveness and observational studies confirmed the high level of protection afforded by the vaccine, leading to its approval in the UK and other European countries.²⁶ By early 2022, the VAXZEVRIA 334 vaccine had been approved by over 170 countries, including Vietnam, making it the most widely deployed vaccine 335 across the globe with over 2.5 billion doses used.²⁶ The induction of superior levels of neutralizing antibodies by 336 COVIVAC and similar activation of CD4+ T cells in comparison to VAXZEVRIA strongly suggest that COVIVAC's 337

- 338 effectiveness would be at least similar.
- The CD4+ and CD8+ T cell response has been assessed using the AIM assay measuring the frequency of spike-specific
 T cell responses. It is important to point out that functional capacity of T cell responses, such as through production
- of cytokines, need to be assessed for a comprehensive picture of vaccine-induced spike-specific T-cell responses.²⁷
- 342 The clinical trial was designed to assess the feasibility of conducting a phase 3 trial in which the benefit of vaccination
- 343 with COVIVAC could be confirmed by demonstrating non-inferior or superior immunogenicity relative to an
- 344 authorized comparator COVID-19 vaccine. That aim was met. Further development of COVIVAC updated to express
- 345 a contemporary recombinant spike protein, administered as a booster dose to vulnerable individuals, is a viable option
- 346 for its manufacturer IVAC, which serves the public sector of Vietnam.

347 Contributors

- VDT and LDM verified the underlying data reported herein. All authors had full access to all the data in the study and
- had final responsibility for the decision to submit for publication. Individual author roles are reported using CRediT:
- 350 Conceptualisation, TCT, NMH, LDM, DHT, LVB, BLI, FK, DW; Data curation, VDT, DDA, VHH, NVT, TCT, JM,
- 351 JMC, NMH, LDM, JF, DHT, DW; Formal analysis, LDM; Funding acquisition, RR, LVB, AS, BLI, FK, DW;
- 352 Investigation, VDT, DDA, VHH, NVT, JM, JMC, EAE, AR, DW; Methodology, RR, LDM, JF, FK, DW; Project
- administration, TCT, NMH, DHT, LVH; Resources, VDT, DDA, NVT, AS, FK, DW; Supervision, VDT, DDA, JM,
- JMC, RR, BLI, FK, DW; Validation, LDM; Visualisation, BLI; Writing-original draft, RR, BLI, FK, DW;
- 355 Writing-review & editing, VDT, DDA, VHH, NVT, TCT, JM, JMC, NMH, LDM, JF, EAE, AR, DHT, LVB, AS.

Declaration of interests

357 The vaccine administered in this study was developed by faculty members at the Icahn School of Medicine at Mount Sinai including FK. Mount Sinai is seeking to commercialize this vaccine; therefore, the institution and its faculty 358 inventors could benefit financially. The Icahn School of Medicine at Mount Sinai has filed patent applications relating 359 360 to SARS-CoV-2 serological assays (U.S. Provisional Application Numbers: 62/994,252, 63/018,457, 63/020,503 and 63/024,436) and NDV-based SARS-CoV-2 vaccines (U.S. Provisional Application Number: 63/251,020) which list 361 362 FK as co-inventor. Patent applications were submitted by the Icahn School of Medicine at Mount Sinai. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, CastleVax, to 363 commercialize SARS-CoV-2 vaccines. FK serves on the scientific advisory board of CastleVax. FK has consulted for 364 365 Merck, Segirus, Curevac and Pfizer, and is currently consulting for Gritstone, Third Rock Ventures, GSK and Avimex. The FK laboratory has been collaborating with Pfizer on animal models of SARS-CoV-2. DW is a consultant for 366 Moderna. AS is a consultant for Gritstone Bio, Flow Pharma, Moderna, AstraZeneca, Qiagen, Fortress, Gilead, Sanofi, 367 368 Merck, RiverVest, MedaCorp, Turnstone, NA Vaccine Institute, Emervax, Gerson Lehrman Group and Guggenheim.LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. 369

370 Data Sharing

- 371 The study protocol is provided in the supplement. Deidentified participant data will be made available for two years
- 372 after publication upon request directed to the lead author Vu Dinh Thiem (vdt@nihe.org.vn). After approval of a data-
- 373 sharing proposal, data can be shared through a secure online platform.

374 Acknowledgments

Work at Mount Sinai was supported by philanthropic donations to Mount Sinai/institutional funding (C-VaRPP funding). Preclinical development of the COVIVAC vaccine was supported, in part, by the Bill & Melinda Gates Foundation [INV-021239]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this

- 379 submission. Initial work on COVIVAC was also supported by institutional funding from the Icahn School of Medicine
- at Mount Sinai. This work has been partially supported by the National Institutes of Health under Contract No.
- 381 75N93019C00065 to A.S, D.W. PATH was also supported by the Coalition for Epidemic Preparedness and a
- 382 charitable contribution from Bayer AG. We thank the University of Texas at Austin for granting IVAC access to their
- 383 6-proline stabilized SARS-CoV-S (Hexapro) technology.

384 **References**

- Duroseau B, Kipshidze N, Limaye RJ. The impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries. Front Public Health. 2022; 10:1087138.
- Ministry of Health portal. COVID-19 epidemic prevention bulletin dated 3/1 of the Ministry of Health.
 Ministry of Health [Internet]. 2023 Mar 1 [cited 2023 Jun 27]; Available from: https://moh.gov.vn/tin-tong-hop/-/asset_publisher/k206Q9qkZOqn/content/ban-tin-phong-chong-dich-covid-19-ngay-3-1-cua-bo-y-te
- World Health Organization. WHO releases global COVID-19 vaccination strategy update to reach 390 3. 391 [Internet]. unprotected. World Health Organization 2022 Jul 22; Available from: 392 https://www.who.int/news/item/22-07-2022-who-releases-global-covid-19-vaccination-strategy-update-to-393 reach-unprotected
- Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021 Jul;27(7):1205–11.
- Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis
 of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022 Jan 7;375(6576):43–50.
- Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell. 2022 Mar 3;185(5):847-859.e11.
- 402 7. Sun W, Liu Y, Amanat F, González-Domínguez I, McCroskery S, Slamanig S, et al. A Newcastle disease
 403 virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nat
 404 Commun. 2021 Oct 27;12(1):6197.
- 8. Duc Dang A, Dinh Vu T, Hai Vu H, Thanh Ta V, Thi Van Pham A, Thi Ngoc Dang M, et al. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Vaccine. 2022 Jun 9;40(26):3621–32.
- 409 9. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the
 410 ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
 411 controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021 Jan;397(10269):99–111.
- 412 10. Bewley KR, Coombes NS, Gagnon L, McInroy L, Baker N, Shaik I, et al. Quantification of SARS-CoV-2
 413 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped
 414 virus neutralization assays. Nat Protoc. 2021 Jun;16(6):3114–40.
- Carreño JM, Alshammary H, Singh G, Raskin A, Amanat F, Amoako A, et al. Evidence for retained spikebinding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA
 vaccine recipients. EBioMedicine. 2021 Nov;73:103626.
- Havenar-Daughton C, Reiss SM, Carnathan DG, Wu JE, Kendric K, Torrents de la Peña A, et al. CytokineIndependent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized
 Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique. The Journal of Immunology.
 2016 Aug 1;197(3):994–1002.

- Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A, et al. Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. PLoS One. 2017 Oct 24;12(10):e0186998.
- 425 14. Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, Gálvez RI, et al. Humoral and cellular immune
 426 memory to four COVID-19 vaccines. Cell. 2022 Jul 7;185(14):2434-2451.e17.
- 427 15. Ogbunude POJ. Efflux of 3H-thymidine by erythrocytes from mice infected with Trypanosoma brucei brucei.
 428 Ann Trop Med Parasitol. 1986 Dec 15;80(6):581–5.
- 16. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb 5;371(6529).
- 431 17. Mateus J, Dan JM, Zhang Z, Rydyznski Moderbacher C, Lammers M, Goodwin B, et al. Low-dose mRNA432 1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. Science. 2021 Oct
 433 22;374(6566):eabj9853.
- 434 18. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses
 435 to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020
 436 Jun;181(7):1489-1501.e15.
- 437 19. Carreño JM, Raskin A, Singh G, Tcheou J, Kawabata H, Gleason C, et al. An inactivated NDV-HXP-S
 438 COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination.
 439 Sci Transl Med. 2023 Feb 15;15(683).
- Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadska D, et al. Towards a population-based
 threshold of protection for COVID-19 vaccines. Vaccine. 2022 Jan;40(2):306–15.
- 442 21. European Medicines Agency. COVID-19 Vaccine (inactivated, adjuvanted) Valneva [Internet]. 2022.
 443 Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-inactivatedadjuvanted-valneva#safety-updates-section
- 44522.Biological E. Limited. Summary of Product Characteristics (SmPC) SARS-CoV-2 (Covid-19) Vaccine446CORBEVAXTM[Internet].2022Feb.Availablefrom:447https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadSmPC/ebio.pdfhttps://cbio.pdffrom:
- 448 23. Grifoni A, Sette A. From Alpha to omicron: The response of T cells. Current Research in Immunology. 2022;3:146–50.
- 450 24. Petrone L, Sette A, de Vries RD, Goletti D. The Importance of Measuring SARS-CoV-2-Specific T-Cell
 451 Responses in an Ongoing Pandemic. Pathogens. 2023 Jun 22;12(7):862.
- 452 25. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet. 2021 Mar;397(10277):881–91.
- 456 26. United Kingdom Department of Health and Social Care, Javid S, Troup M. One year anniversary of UK
 457 deploying Oxford-AstraZeneca vaccine. 2022 Jan 4; Available from: https://www.gov.uk/government/news/one-year-anniversary-of-uk-deploying-oxford-astrazeneca-vaccine
- Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, Gálvez RI, Cortes FH, Grifoni A, Tarke A, Chang
 J, Escarrega EA, Kim C, Goodwin B, Bloom NI, Frazier A, Weiskopf D, Sette A, Crotty S. Humoral and

461 cellular immune memory to four COVID-19 vaccines. Cell. 2022 Jul 7;185(14):2434-2451.e17. doi:
 462 10.1016/j.cell.2022.05.022.

Tables

Table 1: Baseline characteristics of the exposed population

Deseline Chemotorictics	COVIVAC		VAXZEVRIA
Dasenine Characteristics	3 µg (N = 124)	6 μg (N = 125)	(N = 125)
Mean age in years (SD; range)	48.9 (14.82; 18, 75)	48.9 (14.27; 18,77)	49.8 (14.17; 18,74)
Male	64 (51.6%)	67 (53.6%)	54 (43·2%)
Female	60 (48·4%)	58 (46·4%)	71 (56·8%)
Mean body mass index in kg/m2 (SD; range)	22·29 (2·57; 17·01, 31·76)	22·27 (2·67; 17·33, 28·75)	22·24 (2·55; 17·08, 28·88)

467 Table 2: Number of subjects with solicited adverse events during 7 days after vaccination in the safety analysis

468 population.

Reaction		COV	VAXZEVRIA	
		3 μg (N = 124) n (%) (95% CI*)	6 μg (N = 125) n (%) (95% CI*)	(N = 125) n (%) (95% CI*)
Pain/tenderness		57 (46.0%)	65 (52.0%)	90 (72.0%)
	Dose 1	(37.0-55.1)	(42.9-61.0)	(63.3-79.7)
		34 (27.4%)	48 (39.0%)	37 (29.8%)
	Dose 2	(19.8-36.2)	(30.4-48.2)	(22.0-38.7)
		2 (1.6%)	1 (0.8%)	1 (0.8%)
Swelling/induration	Dose 1	(0.2-5.7)	(0.0-4.4)	(0.0-4.4)
		2 (1.6%)	0 (0%)	0 (0%)
	Dose 2	(0.2-5.7)	(0.0-3.0)	(0.0-2.9)
		0 (0%)	0 (0%)	1 (0.8%)
P 4	Dose I	(0.0-2.9)	(0.0-2.9)	(0.0-4.4)
Erythema		1 (0.8%)	0 (0%)	0 (0%)
	Dose 2	(0.0-4.4)	(0.0-3.0)	(0.0-2.9)
		1 (0.8%)	1 (0.8%)	28 (22·4%)
E (20.0C)	Dose I	(0.0-4.4)	(0.0-4.4)	(15.4-30.7)
Fever $(\geq 38 ^{\circ}\mathrm{C})$		3 (2.4%)	3 (2.4%)	2 (1.6%)
	Dose 2	(0.5-6.9)	(0.5-7.0)	(0.2-5.7)
	D 1	31 (25.0%)	52 (41.6%)	63 (50·4%)
II	Dose 1	(17.7-33.6)	(32.9-50.8)	(41.3-59.5)
Headache	Dec 2	28 (22.6%)	28 (22.8%)	26 (21.0%)
	Dose 2	(15.6-31.0)	(15.7-31.2)	(14.2-29.2)
	Dere 1	53 (42.7%)	59 (47·2%)	77 (61.6%)
Fatigue/malaise	Dose 1	(33.9-51.9)	(38.2-56.3)	(52.5-70.2)
	D 2	39 (31.5%)	38 (30.9%)	40 (32·3%)
	Dose 2	(23.4-40.4)	(22.9-39.9)	(24.1-41.2)
Muslais	Deca 1	24 (19·4%)	26 (20.8%)	47 (37.6%)
	Dose I	(12.8-27.4)	(14.1-29.0)	(29.1-46.7)
wiyaigia	Daga 2	21 (16.9%)	14 (11·4%)	23 (18.5%)
	Dose 2	(10.8-24.7)	(6.4-18.4)	(12.1-26.5)
Arthralgia	Deca 1	23 (18.5%)	17 (13.6%)	31 (24.8%)
	Dose 1	(12.1-26.5)	(8.1-20.9)	(17.5-33.3)
	Dose 2	5 (4.0%)	9 (7·3%)	16 (12.9%)
		(1.3-9.2)	(3.4-13.4)	(7.6-20.1)
Nausea/vomiting	Deca 1	10 (8.1%)	9 (7·2%)	13 (10·4%)
	Dose I	(3.9-14.3)	(3·3-13·2)	(5.7-17.1)
	Doso 2	2 (1.6%)	4 (3.3%)	3 (2.4%)
	1056 2	(0.2-5.7)	(0.9-8.1)	(0.5-6.9)

470 Table 3: Summary of geometric mean fold rise (GMFR) from baseline of NT₅₀ titers against SARS-CoV-2

471 pseudovirus by age group in the full analysis population

NT50 MEASURE			COVIVAC		VAXZEVRIA
			3 μg (N = 124)	6 μg (N = 125)	(N = 125)
14 days after the second vaccination (D43)	18-59 yr.	GMFR from baseline (95% CI)	n = 82	n = 83	n = 82
			31.20 (25·14, 38·74)	35·80 (29·03, 44·15)	18·85 (15·10, 23·54)
	\geq 60 yr. GMFR from	GMFR from	n = 42	n = 40	n = 40
		(95% CI)	37·27 (27·43, 50·63)	50·10 (35·46, 70·76)	16·11 (11·73, 22·13)
6 months after the second vaccination (D197)	18-59 yr. GMFR from baseline (95% CI)	GMFR from	n = 80	n = 82	n = 80
		baseline (95% CI)	39·94 (21·56, 73·98)	32·27 (17·73, 58·72)	22·63 (13·72, 37·34)
	≥ 60 yr. GMFR from baseline (95% CI)	n = 40	n = 37	n = 37	
		18·31 (7·73, 43·32)	22·52 (9·26, 54·76)	13·36 (5·61, 31·82)	

473 Figure legends

- 474 **Figure 1. Cohort disposition:** Disposition of subjects recruited and randomized in Phase 2
- Figure 2. Geometric mean titer and 95% CI of NT50 against SARS-CoV-2 pseudotyped virus by age and treatment group in the full analysis population: (a) 18-59 years, (b) \geq 60 years
- 477 Figure 3. SARS-CoV-2 spike-specific CD4+ T cell responses are induced by COVIVAC . (A) FACS example of
- 478 SARS-CoV-2 spike-specific CD4+ T cells evaluated by the AIM assay after stimulation with spike MP. Spike-specific
- 479 CD4+ T cells were quantified by AIM (surface OX40+CD137+) after stimulation with spike peptide megapool (MP).
- 480 (B) Frequencies of SARS-CoV-2 spike-specific CD4+ T cells induced by COVIVAC at 3 μg and 6 μg and
- 481 VAXZEVRIA at day 1 (baseline) and at day 43 post-vaccination. (C) Comparison of spike specific CD4+ T cells
- 482 induced by COVIVAC at 3 µg and 6 µg and VAXZEVRIA at 43 days post-vaccination. (D) FACS example of SARS-
- 483 CoV-2 spike-specific circulating follicular helper T (cTFH) cells (CXCR5+OX40+surface CD40L+, as a percentage
- 484 of CD4+ T cells) after stimulation with spike MP. (E) Frequencies of SARS-CoV-2 spike-specific cTFH cells induced
- 485 by COVIVAC at 3 μg and 6 μg and VAXZEVRIA at day 1 (baseline) and at day 43 post-vaccination. (F) Comparison
- 486 of spike-specific cTFH cells induced by COVIVAC at 3 μg and 6 μg and VAXZEVRIA at 43 days post-vaccination.
- 487 Dotted green lines indicate the limit of quantification (LOQ). Light gray, COVIVAC at 3 μg; red, COVIVAC at 6 μg;
- black, VAXZEVRIA. G) Correlation of spike specific CD4 T cell responses and neutralizing antibody titers measured
- 489 43 days post-vaccination for COVIVAC at 3 µg (grey line) and 6 µg (red line) and VAXZEVRIA (black line). H)
- 490 Comparison of spike specific CD8+ T cells induced by COVIVAC at 3 µg and 6 µg and VAXZEVRIA at 43 days
- 491 post-vaccination. I) Comparison of spike specific CD8+ T cells s induced by COVIVAC at 3 µg and 6 µg and
- 492 VAXZEVRIA at 43 days post-vaccination. The bars in (B, C, E, F, H, I) indicate the geometric mean and geometric
- 493 SD in the analysis of the spike-specific T cell frequencies. Data were analysed for statistical significance using the
- 494 Mann-Whitney U test (B, C, E, F, H, I). Background- subtracted and log data analysed in all cases.

Figure S1: Gating strategy to identify CD4 and CD8 T lymphocytes: Representative gating strategy to define
 CD3+CD4+ and CD3+CD8+ cells by AIM assay.

Figure 1: Cohort disposition





Figure 2: Geometric Mean Titer and 95% CI of NT50 against SARS-CoV-2 pseudovirus by age in the full analysis population: (A) 18-59 years, (B) ≥ 60 years

Figure 3: SARS-CoV-2 spike-specific CD4+ T cell responses are induced by COVIVAC.





